

Competitive Pipeline Brief — Johnson & Johnson

Run date (UTC): 2026-01-08

Source URL	https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
Stored PDF	sources/jnj/2026-01-08.pdf
SHA256	7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04
Extracted 'as of' date	Unknown
Programs extracted	0

Executive summary

Johnson & Johnson Undergoes Significant Pipeline Streamlining and Advancement

Johnson & Johnson's latest pipeline update showcases a substantial restructuring, with over 80 assets and indications removed from the development roadmap. This extensive change predominantly reflects the successful advancement and commercialization of key assets, including new indications or formulations for established blockbusters such as CARVYKTI, DARZALEX, RYBREVANT, AKEEGA, and ERLEADA, particularly bolstering the oncology franchise. Additionally, several late-stage programs in immunology (e.g., nipocalimab, TREMFYA, STELARA) and neuroscience (e.g., CAPLYTA, SPRAVATO) appear to have transitioned from the development pipeline, likely due to regulatory approvals or completion of pivotal trials. Concurrently, a notable number of earlier-stage, wholly-owned 'JNJ-' numbered candidates across various therapeutic areas have also been removed, suggesting a strategic pruning to enhance R&D efficiency and reallocate resources towards programs with higher strategic conviction.

Why it matters

- Reinforces J&J's strong execution in advancing late-stage assets through clinical development to regulatory approval and market, particularly in high-value therapeutic areas.
- Indicates potential for sustained revenue growth and market share expansion from recently approved indications and formulations, especially within the oncology and immunology segments.
- Suggests a more disciplined and focused R&D approach, potentially freeing up resources for higher-priority internal programs, external innovation, or strategic acquisitions.
- May create pipeline gaps in certain early-stage therapeutic areas, necessitating a clear strategy for replenishment through internal discovery or business development.
- Highlights the company's commitment to optimizing its portfolio, allowing for a concentrated effort on programs with the greatest potential for patient impact and commercial success.

Watchlist

- Monitor commercial performance and market uptake of recently launched or expanded products, especially in multiple myeloma (CARVYKTI, TALVEY, TECVAYLI) and prostate cancer (AKEEGA, ERLEADA).
- Watch for official company announcements or investor presentations that provide further clarity on the rationale for specific early-stage asset removals.
- Assess future pipeline updates for new entries or strategic acquisitions that signal J&J's strategy to replenish and diversify its R&D portfolio.

- Analyze Q3/Q4 earnings call transcripts for executive commentary on updated R&D; strategy, pipeline priorities, and potential resource reallocation.
- Keep an eye on competitive landscape developments in therapeutic areas where J&J; has pruned its early-stage pipeline, identifying potential emerging threats or opportunities.

Pipeline snapshot (counts by phase)

No programs extracted in this run.

Change log (previous vs current)

Confidence score (0–1): 0.55

New / Added items

None detected.

Removed / Discontinued items

Asset	Indication	Phase/Change
AKEEGA (niraparib/abiraterone)	M1 Metastatic Castration-Sensitive Prostate Cancer	
Bleximenib	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine	
Bleximenib	Relapsed Refractory Acute Myeloid Leukemia	
CABENUVA	HIV Adolescents	
CAPLYTA (lumateperone)	Adjunctive Treatment for Major Depressive Disorder	
CAPLYTA (lumateperone)	Bipolar Mania	
CAPLYTA (lumateperone)	Pediatric Psychiatric Indications	
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma TNI	
CARVYKTI (Ciltacabtagene autoleucel)	Frontline Multiple Myeloma Transplant Eligible vs ASCT	
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible	
DARZALEX (daratumumab)	Smoldering Multiple Myeloma	
ERLEADA (apalutamide)	High Risk Prostate Cancer	
ERLEADA (apalutamide)	Localized Prostate Cancer	
icotrokinra	Psoriasis	
icotrokinra	Psoriatic Arthritis	
icotrokinra	Ulcerative Colitis	
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis	
IMAAVY (nipocalimab)	Generalized Myasthenia Gravis Pediatrics	
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)	
IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma	
INLEXZO (gemcitabine intravesical system)	High Risk Non Muscle Invasive Bladder Cancer BGC	Experienced

INLEXZO (gemcitabine intravesical System)	Muscle Invasive Bladder Cancer	
INLEXZO (gemcitabine intravesical System)	Muscle Invasive Bladder Cancer BCG-naïve High Risk	
ITI-1284	Alzheimer's Disease-Related Agitation	
ITI-1284	Alzheimer's Disease-Related Psychosis	
ITI-1284	Generalized Anxiety Disorder	
JNJ-0387	Solid Tumors	
JNJ-0631 (ARX305)	Renal Cancer	
JNJ-0683 (ARX788)	Breast Cancer	
JNJ-1493	Hematological Malignancies	
JNJ-1887 sCD59	Geographic Atrophy	
JNJ-1900 (NBTXR3)	Head and Neck Cancer	
JNJ-1900 (NBTXR3)	Lung Cancer	
JNJ-2056 (tau active immunotherapy)	Alzheimer's Disease	
JNJ-2638	Gastrointestinal Cancer	
JNJ-2761	Multiple Myeloma	
JNJ-3413	Lymphoma	
JNJ-4496	Hematological Malignancies	
JNJ-4680	Lung Cancer	
JNJ-4681	Hematological Malignancies	
JNJ-4804 Co-antibody Therapy	Crohn's Disease	
JNJ-4804 Co-antibody Therapy	Psoriatic Arthritis	
JNJ-4804 Co-antibody Therapy	Ulcerative Colitis	
JNJ-4916	Lung Cancer	
JNJ-5108	Immunological Diseases	
JNJ-5120	Major Depressive Disorder	
JNJ-5322	Multiple Myeloma	
JNJ-5939	Atopic Dermatitis	
JNJ-6420	Prostate Cancer	
JNJ-6848	Immunological Diseases	
JNJ-7446	Lung Cancer	
JNJ-7528	Atopic Dermatitis	
JNJ-8177 (ARX517)	Prostate Cancer	
JNJ-8377	Lymphoma	
JNJ-8543	Hematological Malignancies	
JNJ-9401	Prostate Cancer	
JNJ-9530	Hematological Malignancies	
JNJ-9892	Hematological Malignancies	

JNJ-9968	Hematological Malignancies	
macitentan	Pulmonary Arterial Hypertension 75mg	
milvexian (Factor Xla)	Acute Coronary Syndrome	
milvexian (Factor Xla)	Atrial Fibrillation	
milvexian (Factor Xla)	Secondary Stroke Prevention	
nipocalimab	Chronic Inflammatory Demyelinating Polyneuropathy	
nipocalimab	Fetal and Neonatal Alloimmune Thrombocytopenia	
nipocalimab	Hemolytic Disease of the Fetus and Newborn	
nipocalimab	Idiopathic Inflammatory Myopathy	
nipocalimab	Sjogren's Disease	
nipocalimab	Systemic Lupus Erythematosus	
nipocalimab	Warm Autoimmune Hemolytic Anemia	
pasritamig	Prostate Cancer	
posdinemab	Alzheimer's Disease	
RPGR Gene Therapy	Retinitis Pigmentosa	
RYBREVANT (amivantamab)		
RYBREVANT (amivantamab)	Colorectal Cancer	
RYBREVANT (amivantamab)	Colorectal Cancer 2L	
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy	
seltorexant	Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms	
SIMPONI (golimumab)	Pediatric Ulcerative Colitis	
SIRTURO	Leprosy	
SIRTURO	Tuberculosis Long Acting	
SPRAVATO (esketamine)	Major Depressive Disorder with Suicidal Ideation Pediatrics	
SPRAVATO (esketamine)	Treatment Resistant Depression monotherapy	
STELARA (ustekinumab)	Pediatric Crohn's Disease	
STELARA (ustekinumab)	Pediatric Ulcerative Colitis	
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma A-CD38 Naïve	
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma CD38 exposed	
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma	
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed	
TALVEY + TECVAYLI	TIE NDMM in combination with DR	
TAR-210 (RIS/erdafitinib)	Intravesical Delivery System for Localized Bladder Cancer	
TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs	
TECVAYLI (teclistamab)	Relapsed Refractory Multiple Myeloma CD38 exposed	
TECVAYLI (teclistamab)	TE NDMM maintenance	
TECVAYLI (teclistamab)	TIE NDMM in combination with DR	

TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis	
TREMFYA (guselkumab)	Pediatric Psoriasis	
TREMFYA (guselkumab)	Pediatric Ulcerative Colitis	
TREMFYA (guselkumab)	Psoriatic Arthritis Structural Damage	
TREMFYA (guselkumab)	Ulcerative Colitis Subcutaneous Induction	
UPTRA VI (selexipag)	Pediatric Pulmonary Arterial Hypertension	

Phase changes

None detected.